depression treatment

News of psychedelics and who is using them keeps making headlines. From athletes and Silicon Valley executives to next-door neighbors, an increasing number of people are trying these substances in the hopes of getting relief from unendurable mental health conditions.  Hollywood...

Clinical-stage biotech company Delix Therapeutics announced the initial cohort of its first-in-human Phase 1 trial assessing the safety and efficacy of a new non-hallucinogenic, MDMA and 5-MeO-DMT inspired psychoplastogen has successfully been dosed. Taking place in the Netherlands-based CHRD with...

In response to the question of how psychedelics can prove effective in treating mental health conditions like depression, an international neuroscience team seems to have found a new answer. Published in the Nature Neuroscience journal, results from the preclinical research show that LSD...

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its novel DMT-based synthetic compound. Conducted at Hammersmith Medicines Research Ltd. in the U.K.,...

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial met its primary endpoint with 7 of 8 patients (87.5%) in remission at day 7 after...

Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray (Spravato) for treatment-resistant depression (TRD) in adults. Related Link: EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In...

The FDA has cleared BrainsWay Ltd's (NASDAQ: BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious depression. BrainsWay submitted data from 573 patients in support of its...

Praxis Precision Medicines Inc (NASDAQ: PRAX) has reported results from its PRAX-114 Phase 2a Part B proof-of-concept trial for perimenopausal depression (PMD). PRAX-114 60 mg suspension formulation (n=6) for 14 days in an outpatient setting showed rapid and sustained improvements...

Peter Thiel-backed Atai Life Sciences (NASDAQ: ATAI) has launched a new portfolio company, Revixia Life Sciences. Revixia Life's primary mission is to develop Salvinorin A (SalA) to treat various mental health disorders. Derived from Salvia divinorum, SalA is a non-...